Updated 90d ago
PIKTOR, an oral serabelisib/sapanisertib combination targeting the PI3K/AKT/mTOR pathway, is in Phase 2 for second-line PI3K-mutant advanced endometrial cancer and Phase 1b/2 for HR+/HER2- advanced breast cancer. The thesis resolves on whether Phase 2 topline endometrial data confirm the 71% Phase 1b response rate at a level sufficient to support regulatory advancement. The primary risks are competition from Iovance's lifileucel in the same platinum/PD-1-failed endometrial population and resistance emergence across dual mTOR/PI3K blockade, a known liability of this pathway class.
Thesis drivers
What is holding the thesis up
What could change the thesis
The events that would break it
Generated from public SEC filings and disclosures. For informational purposes only — not investment advice. Always conduct your own research before making investment decisions.
Thesis log
Tracked in real time as it happened — not reconstructed after the fact
Key value driver
The most decisive event ahead
Bull and bear case
Both sides of the thesis, argued
Pipeline
4 programs · 4 catalysts